Movement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11

Market Focus

06/15

On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.

Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.

Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1168018671"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168018671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168018671?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168018671","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11","media":"Market Focus","content":"<p><p>On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.</p><p>Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.</p><p>Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-06-15 23:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.</p><p>Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.</p><p>Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特醫療","start_time":0,"source_url":"","article_id":"1168018671","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168018671","pubTimestamp":1781535878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.Within the Biotechnology sector where Incyte belongs, the overall sector performance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"走势提示|Incyte常规交易下跌5.37%，报104.11美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}